Changes in anti-viral effectiveness of interferon after dose reduction in chronic hepatitis C patients: a case control study (Q24797971)

2

0 references

J T Brouwer

3

0 references

R S Levi-Drummer

4

0 references

S W Schalm

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

5

0 references

language of work or name

English

0 references

publication date

2001

0 references

published in

BMC Gastroenterology

0 references

volume

1

0 references

issue

1

0 references

page(s)

14

0 references

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=64636

Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=64636

Epidemiology of hepatitis C

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=64636

Genotype dependence of hepatitis C virus load measurement in commercially available quantitative assays.

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=64636

Comparative stabilities of quantitative human immunodeficiency virus RNA in plasma from samples collected in VACUTAINER CPT, VACUTAINER PPT, and standard VACUTAINER tubes.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=64636

Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=64636

Quantification of the initial decline of serum hepatitis C virus RNA and response to interferon alfa

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=64636

Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=64636

Effect of interferon alfa on the dynamics of hepatitis C virus turnover in vivo

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=64636

Treatment of chronic hepatitis C with high-dose interferon alpha-2b. A multicenter study

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=64636

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

30 May 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-230X-1-14

Ultrarapid hepatitis C virus clearance by daily high-dose interferon in non-responders to standard therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-230X-1-14

Estimation of early hepatitis C viral clearance in patients receiving daily interferon and ribavirin therapy using a mathematical model

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-230X-1-14

Efficacy of interferon dose and prediction of response in chronic hepatitis C: Benelux study in 336 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-230X-1-14

Hepatitis C viral kinetics in difficult to treat patients receiving high dose interferon and ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-230X-1-14

Peginterferon alfa-2a in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-230X-1-14

Interferon alfa-2b for chronic hepatitis C: effects of dose increment and duration of treatment on response rates. Results of the first multicentre Australian trial. Australia Hepatitis C Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-230X-1-14